康霈* News Releases

Kangpei Announces Board Resolution to Refrain from Loss Coverage and Dividend Distribution for Q2 115

Kangpei's board of directors resolved on August 3, 115, to refrain from loss coverage and dividend d… · 2026-08-03

Kangpei Announces Board Approval of Consolidated Financial Report for Q2 2026

Kangpei announced that its board of directors and audit committee approved the consolidated financia… · 2026-08-03

Kangpei Completes FDA IND Submission for Phase 2 Trial of CBL-514 Injection in Combination with tirzepatide (Eli Lilly) for Abdominal Subcutaneous Fat Reduction in Overweight or Obese Adults

On July 27, 2026, Kangpei completed the IND submission to the U.S. FDA for a multicenter Phase 2 cli… · 2026-07-27

Kangpei Announces Expected Board Meeting Date for Q2 2026 Consolidated Financial Report

Kangpei has announced that the board meeting to review the consolidated financial report for the sec… · 2026-07-24

Kangpei Biotech's Phase 3b Long-Term Follow-Up Clinical Trial CBL-0303 for CBL-514 Injection to Reduce Abdominal Subcutaneous Fat Has Cleared the U.S. FDA's 30-Day IND Review Period, Trial to Commence

Kangpei Biotech announces that its Phase 3b long-term follow-up clinical trial CBL-0303 for CBL-514 … · 2026-07-03

Kangpei Announces Board Resolution to Buy Back and Cancel Restricted Employee Share Rights for Capital Reduction

Kangpei announced a board resolution to carry out capital reduction by canceling restricted employee… · 2026-06-26

Kangpei Biotech Announces Board Resolution on Issuance of Restricted Stock Units for 2025 Fiscal Year

Kangpei Biotech Co., Ltd. has resolved to issue 23,000 new restricted stock units for its employees … · 2026-06-26

Kangpei Announces Board Resolution to Amend the '115th Fiscal Year Employee Stock Option Certificate Issuance and Exercise Method'

Kangpei announced that its board of directors resolved on June 26, 115, to amend certain provisions … · 2026-06-26

Kangpei Announces Board Resolution to Amend the 2025 Restricted Stock Unit Issuance Plan

Kangpei's board of directors resolved on June 26, 2026, to revise its 2025 Restricted Stock Unit (RS… · 2026-06-26

Kangpei Announces HREC Approval in Australia for CBL-0302, the Second Global Pivotal Phase 3 Trial of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Kangpei has announced that its second global pivotal Phase 3 clinical trial, CBL-0302 (SUPREME-02), … · 2026-06-18

Kangpei*: March 2026 Monthly Revenue NT$0.00 Million (YoY Change N/A)

Kangpei*, a company in the biotechnology and medical industry, reported a minimal monthly revenue of… · 2026-03-01

【Canopy*】February 2026 Revenue: 0.00 Billion (YoY )

Canopy* (6919) has announced its financial report for February 2026. The company's revenue for the m… · 2026-02-01

【康霈】FDA Submission Completed for Phase 3b Long-Term Follow-up Clinical Trial of CBL-514 for Abdominal Fat Reduction

康霈生技 announced on June 3, 2026, the submission of its Phase 3b long-term follow-up clinical trial (C… · 2026-06-03

[Canpep*] Company's New Drug CBL-514 Injection for Abdominal Subcutaneous Fat Reduction, Second Pivotal Phase 3 Trial (CBL-0302) Clears US FDA IND 30-Day Review, Trial to be Initiated

Biotech firm Canpep Inc. announced that its second pivotal Phase 3 clinical trial (CBL-0302) for the… · 2026-05-18

Canopy's Fat-Reduction Drug CBL-514 Gets US FDA Go-Ahead for Second Pivotal Phase 3 Trial

Canopy Biosciences announced that its IND application for the second multi-national, multi-center pi… · 2026-05-18

[KangPai] Announcement of Board (including Independent Directors) Re-election at 2026 Annual General Meeting

KangPai Biotech held its annual general meeting on May 22, 2026, and completed a comprehensive re-el… · 2026-05-22

【KangPei*】Announcement of Important Resolutions at the 115 Annual General Meeting

KangPei held its Annual General Meeting on May 22, 115, approving the 114 fiscal year financial stat… · 2026-05-22

[康霈*] Phase 3 clinical trial for CBL-514 injection to reduce abdominal subcutaneous fat approved in Canada.

康霈* announced that its second multi-center Phase 3 clinical trial (CBL-0302) for the new drug CBL-51… · 2026-05-28

[Kang-Pei] Participation in the '2026 Q2 Global Investment Forum' hosted by Taishin Securities

Kang-Pei Biotech has been invited to participate in the '2026 Q2 Global Investment Forum' hosted by … · 2026-05-26

[Kangpe] CBL-514 Injection Files for the Second Multi-national Pivotal Phase 3 Clinical Trial (CBL-0302) with Australian HREC

Kangpe Biotechnology announced on May 20, 2026, that it has completed the clinical trial application… · 2026-05-20

[Kangstem] Announcement Regarding the Election of the Chairman of the Board

Kangstem Biotech held its 9th Board of Directors meeting on May 22, 2026, to elect a new Chairman fo… · 2026-05-22

[Kangpu] Announcement of the 3rd Audit Committee Member List

Kangpu Biotech announced its 3rd Audit Committee member list on May 22, 2026, due to the expiration … · 2026-05-22

[Kang霈] Announcement of the Appointment of the 3rd Remuneration Committee Members

Kang霈 has appointed Lin Ching-Po, Lo Pao-Chu, and Peng Hsien-Li as members of its 3rd Remuneration C… · 2026-05-22

[ConMed] Shareholder Meeting Resolution Passed to Waive Non-compete Restrictions for Director

ConMed Biotech held a general shareholder meeting on May 22, 2026, and approved the resolution to wa… · 2026-05-22

KangPu's CBL-514 Injectable for Subcutaneous Fat Reduction Approved for Phase 2 Trial by Taiwan TFDA

KangPu has received approval from the Taiwan TFDA for its Phase 2 clinical trial (CBL-0206) for CBL-… · 2026-05-19

KangPao* Announces Significant Financial and Business Information Due to Securities Reaching Disclosure Standard in Centralized Trading Market

KangPao* has disclosed significant financial and business information as its securities reached the … · 2026-04-09

[Kangpu*] Announcement: Company's Second Multinational, Multicenter Pivotal Phase 3 Clinical Trial (CBL-0302) of New Drug CBL-514 Injection for Reducing Abdominal Subcutaneous Fat, Health Canada CTA Submission Completed Today

Kangpu announced the completion of its Clinical Trial Application (CTA) to Health Canada for CBL-030… · 2026-04-30

[Caliway] May 2026 Revenue Reaches NT$0.00 Billion (YoY Change N/A)

Biotechnology company Caliway Biopharmaceuticals announced its consolidated revenue for May 2026 at … · 2026-05-01

【Caliway*】Company's new drug CBL-514 injection for reducing abdominal subcutaneous fat, Asia-Pacific Phase II clinical trial CBL-0206, has completed Taiwan TFDA IND application today.

Caliway Biomedical (康霈) announced the completion of its Taiwan TFDA IND application for CBL-514 inje… · 2026-04-28

【KangHui*】April 2026 Revenue: 4 Million (YoY -70.8%)

KangHui* (6919), a biotechnology and healthcare company, reported April 2026 revenue of 3.57 million… · 2026-04-01

[Kangpu*] Announcement: Company's Second Multinational, Multicenter Pivotal Phase 3 Clinical Trial (CBL-0302) of New Drug CBL-514 Injection for Reducing Abdominal Subcutaneous Fat, Health Canada CTA Submission Completed Today

Kangpu announced the completion of its Clinical Trial Application (CTA) to Health Canada for CBL-030… · 2026-04-30

【Caliway*】Company's new drug CBL-514 injection for reducing abdominal subcutaneous fat, Asia-Pacific Phase II clinical trial CBL-0206, has completed Taiwan TFDA IND application today.

Caliway Biomedical (康霈) announced the completion of its Taiwan TFDA IND application for CBL-514 inje… · 2026-04-28

[Caliway] CBL-514 Phase 2 Clinical Trial for Fat Reduction Approved in Australia

Caliway Biopharmaceuticals announced that its new drug CBL-514 injection for subcutaneous fat reduct… · 2026-04-23

Clover Announces Completion of US FDA IND Submission for Second Pivotal Phase 3 Clinical Trial of CBL-514 Injection for Abdominal Fat Reduction

Clover Biopharmaceuticals announced that the second pivotal Phase 3 clinical trial (SUPREME-02, code… · 2026-04-20

KangPao* Announces Significant Financial and Business Information Due to Securities Reaching Disclosure Standard in Centralized Trading Market

KangPao* has disclosed significant financial and business information as its securities reached the … · 2026-04-09

[Caliway] CBL-514 Phase 2 Clinical Trial for Fat Reduction Approved in Australia

Caliway Biopharmaceuticals announced that its new drug CBL-514 injection for subcutaneous fat reduct… · 2026-04-23

Clover Announces Completion of US FDA IND Submission for Second Pivotal Phase 3 Clinical Trial of CBL-514 Injection for Abdominal Fat Reduction

Clover Biopharmaceuticals announced that the second pivotal Phase 3 clinical trial (SUPREME-02, code… · 2026-04-20

Kangpei*: March 2026 Monthly Revenue NT$0.00 Million (YoY Change N/A)

Kangpei*, a company in the biotechnology and medical industry, reported a minimal monthly revenue of… · 2026-03-01

KangPao* Announces Significant Financial and Business Information Due to Securities Reaching Disclosure Standard in Centralized Trading Market

KangPao* has disclosed significant financial and business information as its securities reached the … · 2026-04-09

【Canopy*】February 2026 Revenue: 0.00 Billion (YoY )

Canopy* (6919) has announced its financial report for February 2026. The company's revenue for the m… · 2026-02-01

【KangHui*】April 2026 Revenue: 4 Million (YoY -70.8%)

KangHui* (6919), a biotechnology and healthcare company, reported April 2026 revenue of 3.57 million… · 2026-04-01